N-Methyl-5-hydroxypentanamid | 41124-49-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-Methyl-5-hydroxypentanamid
• 英文别名: 5-hydroxy-N-methylpentanamide
• CAS: 41124-49-6
• 化学式: C₆H₁₃NO₂
• 分子量: 131.175
• InChiKey: LWPBAPIJFUKIFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  delta-戊内酯 、 甲胺 以 四氢呋喃 为溶剂， 生成 N-Methyl-5-hydroxypentanamid
  参考文献：
  名称：

  8-氮杂-和10-氧杂-8,12-β-羟基前列腺素的合成及其胃分泌特性。

  摘要：

  DOI：

  10.1021/jm00210a035

文献信息

• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSES ORGANIQUES
  申请人：SPEEDEL EXPERIMENTA AG

  公开号：WO2005090304A1

  公开（公告）日：2005-09-29

  The invention relates to novel amino alcohols of the general formula (I) where X, R1, R2, R3, R4, R5 and R6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

  这项发明涉及一般式(I)的新型氨基醇，其中X、R1、R2、R3、R4、R5和R6的定义详细描述在说明书中，以及它们的制备方法和将这些化合物用作药物，特别是作为肾素抑制剂。
• Heterocyclic-substituted alkanamides as therapeutic compounds
  申请人：Speedel Experimenta AG

  公开号：EP1958666A1

  公开（公告）日：2008-08-20

  Use of compounds of the general formula (I) and pharmaceutically acceptable salt thereof, in which R1 and R2 have the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.

  使用一般式（I）及其药用盐的化合物，其中R1和R2的定义在描述中详细说明，作为β-分泌酶、半胱氨酸蛋白酶D、血浆蛋白酶II和/或HIV蛋白酶抑制剂。
• Fluorene Compound and Pharmaceutical Use Thereof
  申请人：Motomura Takahisa

  公开号：US20100240634A1

  公开（公告）日：2010-09-23

  The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.

  本发明提供了一种用于预防或治疗糖尿病、糖尿病并发症、胰岛素抵抗综合征、代谢综合征、高血糖、血脂异常、动脉粥样硬化、心力衰竭、心肌病、心肌缺血、脑缺血、脑卒中、肺动脉高压、高乳酸血症、线粒体疾病、线粒体脑病或癌症的药剂，即PDHK抑制剂等。一种由下式[I]表示的化合物或其药学上可接受的盐，或其溶剂：其中每个符号如规范中所定义。
• Diaminoalcohol derivatives for the treatment of Alzheimer, malaria, HIV
  申请人：Speedel Experimenta AG

  公开号：EP1764099A2

  公开（公告）日：2007-03-21

  Use of compounds of the general formula (I) wherein R1, R2, R3, R4, R5, R6 and X have the definitions elucidated in more detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.

  使用一般式(I)中的化合物，其中R1、R2、R3、R4、R5、R6和X的定义在描述中有更详细的阐述，作为β-分泌酶、猫hepsin D、plasmepsin II和/或HIV蛋白酶抑制剂。
• Beta-alanine derivatives and their use as receptor anatgonists
  申请人：——

  公开号：US20030018193A1

  公开（公告）日：2003-01-23

  A beta-alanine derivative of the formula (I) wherein R 1 is hydrogen atom or an amino protective group; A is a lower alkylene group or a lower alkenylene group; R 2 is hydrogen atom or an amino group which may be substituted with an acyl group; R 3 is hydrogen atom or an aryl or aralkyl group which may be substituted with one or more of hydroxy and/or lower alkoxy, a moiety represented by the formula (II), which is a bivalent N-containing 6- to 8-membered heterocyclic group, or a pharmaceutically acceptable salt thereof.

  公式（I）的β-丙氨酸衍生物，其中R1是氢原子或氨基保护基团；A是较低的烷基或较低的烯基基团；R2是氢原子或氨基团，可能被酰基取代；R3是氢原子或芳基或芳基基团，可能被一个或多个羟基和/或较低的烷氧基取代，由公式（II）表示的基团，该基团是一种双价的含氮6-到8-成员杂环基团，或其药用盐。